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A novel candidate metastasis modifier, ribosomal RNA processing 1 homolog B (Rrp1b), was identified through two
independent approaches. First, yeast two-hybrid, immunoprecipitation, and functional assays demonstrated a physical
and functional interaction between Rrp1b and the previous identified metastasis modifier Sipa1. In parallel, using
mouse and human metastasis gene expression data it was observed that extracellular matrix (ECM) genes are common
components of metastasis predictive signatures, suggesting that ECM genes are either important markers or causal
factors in metastasis. To investigate the relationship between ECM genes and poor prognosis in breast cancer,
expression quantitative trait locus analysis of polyoma middle-T transgene-induced mammary tumor was performed.
ECM gene expression was found to be consistently associated with Rrp1b expression. In vitro expression of Rrp1b
significantly altered ECM gene expression, tumor growth, and dissemination in metastasis assays. Furthermore, a gene
signature induced by ectopic expression of Rrp1b in tumor cells predicted survival in a human breast cancer gene
expression dataset. Finally, constitutional polymorphism within RRP1B was found to be significantly associated with
tumor progression in two independent breast cancer cohorts. These data suggest that RRP1B may be a novel
susceptibility gene for breast cancer progression and metastasis.
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Introduction
Most cancer-related mortality is a consequence of meta-
stasis, and the vast majority of deaths from breast cancer, the
most common malignancy of women in the United States [1],
are attributable to disseminated disease. Disseminated breast
cancer is still considered incurable in spite of therapeutic
advances [2], and a more comprehensive understanding of the
biology of tumor progression is therefore necessary to
facilitate development of improved treatments. This includes
the ability to spare women at low risk of metastasis from
needless additional therapy, while allowing earlier initiation
of aggressive treatment to reduce the incidence and extent of
metastasis in women with poorer prognoses.
We previously demonstrated the signiﬁcant inﬂuence of
germline variation on tumor progression [3,4], which allowed
us to identify the ﬁrst known heritable mouse gene that
modulates metastasis [5,6], the Rap-GTPase activating protein
(GAP) Sipa1 [7]. Subsequent human studies demonstrated that
SIPA1 polymorphisms are associated with metastatic cancer
[7] and poor outcome in breast cancer [8], validating the
utility of the highly metastatic polyoma middle-T (PyMT)
transgenic mouse model to identify relevant human metastasis
modiﬁers. The current study represents the convergence of
two parallel strategies to enhance our understanding of the
role of heritable factors in metastasis. Using in vitro, genetic,
and epidemiologic analyses, we have identiﬁed ribosomal
RNA processing 1 homolog B (Rrp1b) as a factor that
physically interacts with the metastasis modiﬁer gene, Sipa1,
modulates elements of metastasis predictive gene expression
signatures, suppresses tumor progression in animal models,
and is associated with progression and survival in pilot human
breast cancer epidemiology cohorts. This integrated approach
suggests that Rrp1b is a novel tumor progression and meta-
stasis susceptibility locus in both mice and humans.
Results
Rrp1b Forms a Complex with Sipa1 and Inhibits Sipa1 Gap
Activity
Previous mouse studies demonstrated that a polymorphism
in Sipa1 in the region encoding a PDZ protein–protein
interaction domain is associated with metastasis [7]. Yeast
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identify additional genes potentially involved in metastasis
(Table S1). Following sequence alignment, 29 clones were
found to bind to at least one of the SIPA1 baits (Table S2).
One of these was RRP1B (the human homolog of Rrp1b),
which was identiﬁed by a probe spanning the PDZ domain.
To conﬁrm the interaction, HEK293 cells were cotrans-
fected with epitope-tagged mouse Rrp1b and Sipa1. AQP2,
which also interacts with the PDZ domain of Sipa1, was
cotransfected with Sipa1 as a positive control. Cell extracts
were then immunoprecipitated with Sipa1 antibodies and
blotted with V5-antibodies (V5 was the epitope fused to
Rrp1b in this experiment), revealing an Rrp1b-speciﬁc band
(Figure 1A, upper panel, lane 5). Conversely, when HA-tagged
Rrp1b was cotransfected with V5-tagged Sipa1, immunopre-
cipitation with an HA-antibody followed by western blotting
yielded a Sipa1-speciﬁc band (Figure 1B, upper panel, lane 3).
As further validation, the functional consequence of the
Rrp1b–Sipa1 interaction on the Rap-GTPase enzymatic
activity of Sipa1 was examined. HEK293 cells were cotrans-
fected with a Rap exchange factor, Epac, and Sipa1 in the
presence of AQP2 or Rrp1b (Figure 1C). AQP2, which has
been shown previously to interfere with the RapGAP activity
of Sipa1 [7], was used as a positive control. In the absence of
Sipa1, Epac induced an increase in Rap-GTP, regardless of
whether the cells also expressed AQP2 or Rrp1b (upper panel,
lanes 1–3), indicating that Rrp1b did not directly affect Rap-
GTP levels. As expected, the presence of Sipa1 reduced Epac-
induced Rap-GTP levels (upper panel, lane 4). This reduction
was partially inhibited by AQP2 or Rrp1b (upper panel, lanes
5 and 6, respectively). Thus Rrp1b, like AQP2, inhibits the
RapGAP activity of Sipa1.
Expression QTL Mapping in AKXD Recombinant Inbred
Mice
Examination of published reports describing primary
human breast tumor expression proﬁles predicting metastasis
or disease outcome reveals a common association with the
expression levels of extracellular matrix (ECM) genes [9–11].
Similar ECM-rich metastasis-predictive signatures also exist
in PyMT-induced mouse mammary tumors [12]. The con-
sistent association of ECM gene expression levels with
outcome suggests that differential ECM gene expression is
either a causative factor or marker of metastatic potential.
In a set of experiments performed concurrently with our
efforts to identify proteins interacting with SIPA1, the
relationship between ECM gene expression and metastasis
susceptibility was further characterized by investigating the
inherited origins of metastasis-predictive gene signatures.
Speciﬁcally, expression quantitative trait locus (eQTL) map-
ping of ECM gene expression was performed to identify
genomic regions associated with ECM gene expression (see
Text S1). To achieve this, we analyzed microarray data
derived from PyMT-induced primary tumors in the AKXD
RI panel recombinant inbred (RI) mice [13,14], a panel of RI
mice derived from high metastatic potential AKR/J and low
metastatic potential DBA/2J strains [3]. An Internet-based
analytical package/repository that allows for analysis of RI
microarray expression data called WebQTL [15,16] was used
to map ECM eQTLs. Reproducible, statistically signiﬁcant or
suggestive ECM eQTLs were discovered on chromosomes 7,
17, and 18 (see Figure 2 and Text S1), implying that loci from
these three regions regulate much of the metastasis-predictive
ECM gene expression in AKXD tumors. The chromosome 17
locus (Figure S1) was of particular interest, as its peak linkage
region (;29.5 Mb) colocalizes with a previously described
metastasis efﬁciency and tumor growth kinetics QTL [6], and
encompasses the physical location of Rrp1b (;29.9 Mb).
Based on the current prevailing hypothesis that most
modiﬁers are likely to result from modest variations in gene
expression levels or mRNA stability [16,17], identiﬁcation of
potential candidates for the chromosome 17 ECM modiﬁers
was performed by correlation analysis. Genes were correlated
with ECM gene expression on a genome-wide scale using the
Trait Correlation function of WebQTL. The results were
subsequently ﬁltered to examine only those genes that were
present under each of the ECM eQTL peaks. Thirty genes
located within a genomic region spanning the peak likelihood
ratio statistic (LRS) score (physical locations on chromosome
17 ; 18–40 Mb) displayed both a high degree of correlation
and a low p value with regard to expression of two or more of
the nine probes within metastasis-predictive ECM genes
(Table S3). Rrp1b was one of those genes that displayed high
levels of expression correlation with ECM gene probes (Table
S3). This gene was selected for further analysis for the
following reasons: (a) its physical proximity to the peak eQTL
linkage; (b) its apparent correlation with expression of
various metastasis-predictive ECM genes; and (c) that it had
also been identiﬁed as interacting with the metastasis
efﬁciency modiﬁer Sipa1. The effects of other genes within
the eQTL linkage region upon metastasis remain under
investigation, but their potential role in the modulation of
metastasis efﬁciency (if any) is beyond the scope of the
current study.
Ectopic Expression of Rrp1b Modulates ECM Gene
Expression
To conﬁrm the role of Rrp1b in the regulation of ECM
expression, cell lines stably over-expressing Rrp1b were
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Author Summary
Metastasis, which is defined as the spread of malignant tumor cells
from their original site to other parts of the body, accounts for the
vast majority of solid cancer-related mortality. Our laboratory has
previously shown that host germline-encoded variation modifies
primary tumor metastatic capacity. Here, we detail how germline-
encoded Rrp1b variation likely modulates metastasis. In mice,
constitutional Rrp1b variation correlates with ECM gene expression,
which are genes commonly differentially regulated in metastasis
prone tumors. Furthermore, we demonstrate that Rrp1b expression
levels are modulated by germline variation in mice with differing
metastatic propensities, and that variation of Rrp1b expression in a
highly metastatic mouse mammary tumor cell line modifies
progression. Differential RRP1B functionality also appears to play
an important role in human breast cancer progression. Specifically,
we demonstrate that a microarray gene expression signature
indicative of differential RRP1B expression predicts breast cancer-
specific survival. Furthermore, we show that germline-encoded
RRP1B variation is associated with markers of outcome in two breast
cancer populations. In summary, these data suggest that Rrp1b may
be a germline-encoded metastasis modifier in both mice and
humans, which leads to the possibility that knowledge of RRP1B
functionality and variation in breast cancer might facilitate improved
assessment of prognosis.generated in the highly metastatic mouse mammary tumor
cell lines Mvt-1, which is derived from FVB/NJ mice [18] and
4T1, which is derived from BALB mice [19]. Multiple
individual clones were generated by clonal dilution, and
ectopic expression of Rrp1b conﬁrmed by quantitative real-
time PCR (qPCR) (ratio of Rrp1b expression in Mvt-1/Rrp1b
versus controls ¼ 3.28 6 0.41; p ¼ 0.001 and ratio of Rrp1b
expression in 4T1/Rrp1b versus controls ¼ 4.55 6 0.95; p ¼
0.015). Metastasis-predictive ECM gene expression was then
quantiﬁed, and expression of eight of the 12 quantiﬁed ECM
genes (Col1a1, Col3a1, Col6a2, Fbln2, Fbn1, Mfap5, Serpinf1, and
Serping1; see Table 1) was signiﬁcantly changed in response to
ectopic Rrp1b expression in the Mvt-1 cell line. Expression
analysis of ﬁve of six signiﬁcantly dysregulated genes in the
4T1 cell lines changed in the same direction as the Mvt-1/
Rrp1b cells (Table 1), suggesting that Rrp1b modulation of
ECM genes was not a unique characteristic of the Mvt-1
epithelial cell line. To conﬁrm that these results were not an
artifact of the Mvt-1 and 4T1 tumor cell lines, the experiment
was repeated in NIH-3T3 ﬁbroblasts. Of the six metastasis-
predictive ECM genes dysregulated in all three cell lines, four
showed the same proﬁle in response to ectopic Rrp1b
expression. The remaining discrepancies are likely due to
experimental variability, differently regulated genes in
epithelial (i.e., Mvt-1, 4T1) and mesenchymal cells (i.e., NIH-
3T3), or the effects of the differing genetic backgrounds of
the three cell lines.
Growth curves were plotted for the Mvt-1 cell lines to
conﬁrm that the observed changes in gene expression in did
not result from differential cellular growth rates (Figure S2).
The growth of Rrp1b-transfected cell lines did not signiﬁ-
cantly differ from the growth rate of the control cell lines
implying that the observed differences in metastasis-predic-
tive gene expression are intrinsically related to the effects of
Rrp1b rather than secondary to reduced growth kinetics.
Similarly, no differences in growth rates were observed with
the 4T1 and NIH-3T3 cells ectopically expressing Rrp1b
compared to control cell lines (unpublished data).
Tumor Growth and Metastatic Potential Are Reduced by
Ectopic Expression of Rrp1b
Spontaneous metastasis assays were performed by subcuta-
neously implanting equal amounts of either Mvt-1/Rrp1b or
Mvt-1/b-galactosidase clones into virgin FVB/NJ female mice.
Speciﬁcally, the in vivo growth characteristics of four Mvt-1/
Rrp1b clones were compared to that of one Mvt-1/b-
galactosidase cell line. Since previous experiments have
demonstrated that the in vitro and in vivo growth character-
istics of the multiple independent isolates of the control cell
line are virtually identical to those of the wild-type cell line,
only one such cell line was used to minimize the number of
animals in accordance with National Cancer Institute Animal
Care and Use guidelines. Tumor weight and lung surface
metastasis count were quantiﬁed following a four-week
incubation period. Both tumor growth and lung surface
metastasis were signiﬁcantly reduced in Mvt-1/Rrp1b clonal
isolates. Average tumor weight was 240 mg 6 200 mg for the
Rrp1b clones compared to 600 mg 6 270 mg for the b-
galactosidase clone (p , 0.001) (Figure 3A), and average lung
Figure 1. Rrp1b Forms a Complex with Sipa-1 and Inhibits its RapGAP Activity
(A) and (B) Complex formation between Rrp1b and Sipa1, and between AQP2 and Sipa1. AQP2 or Rrp1b-V5 (A) or Rrp1b-HA (B) was expressed singly or
coexpressed with Sipa1-V5 in 293 cells as indicated. In (A), anti-Sipa1 immunocomplexes were immunoblotted with anti-V5 antibodies (top western blot
(WB) panel) or anti-AQP2 antibodies (next WB panel). In (B), anti-Rrp1b-HA immunocomplexes were immunoblotted with anti-Sipa1-V5 antibody (WB
panel). In the two lower panels of A and B, the immunoblots show the expression in cell extracts of exogenous Rrp1b-V5, Sipa1-V5, AQP2, and Rrp1b-HA.
(C) Inhibition of Sipa1 RapGAP Activity by AQP2 and Rrp1b. In cells expressing Epac, Sipa1-V5 was expressed with AQP2 or Rrp1b-V5 as indicated. The in
vivo Rap1GTP levels were assayed by RalGDS-RBD pull-down (top panel). In the lower panels, the immunoblots show the expression of endogenous
Rap1, and the exogenous proteins: Sipa1-V5, Rrp1b-V5, AQP2, and Epac-HA. The Rap1 and EpacHA immunoblots also serve as loading controls.
doi:10.1371/journal.pgen.0030214.g001
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Rrp1b Modulates Cancer Progression and MetastasisFigure 2. eQTL Analysis in the AKXD RI Mouse Panel
Analysis of metastasis class-predictive ECM gene component expression patterns in PyMT transgene-induced tumors in AKXD recombinant inbred mice
reveals the presence of three relatively consistent eQTLs on chromosomes 7, 17, and 18. The diagram on the left shows an eQTL cluster map generated
with WebQTL. The warm hues reflect an LRS for increased transcription in mice with the DBA/2J genotype at any given locus, and the cool hues
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Rrp1b Modulates Cancer Progression and Metastasissurface metastasis count being 5.7 6 6.0 for the Rrp1b clones
compared to 12.6 6 8.4 for the b-galactosidase clone (p¼0.010)
(Figure 3B).
Rrp1b Promoter Is More Active in Low-Metastatic DBA/2J
Than in High-Metastatic AKR/J
Genomic sequencing of Rrp1b was performed from high
(AKR/J, FVB/NJ) and low (I/lnJ, DBA/2J, and NZB/B1NJ)
metastatic inbred strains to identify polymorphisms that
might account for the differential ECM gene expression. Of
particular interest were polymorphisms identiﬁed in the
AKR/J and DBA/2J strains, since these are the progenitors of
the AKXD RI panel. In addition to multiple intronic
polymorphisms, the AKR/J Rrp1b proximal promoter con-
tained two adenosine insertion polymorphisms located 1,132
bp and 1,540 bp upstream of the transcription initiation site.
Rrp1b polymorphisms in all strains are listed in Table S4.
To examine the functional consequences of the AKR/J
promoter polymorphisms, a region 1.67 kb upstream of the
transcription initiation site of Rrp1b from AKR/J and DBA/2J
was cloned into pBlue-TOPO (Invitrogen). Following normal-
ization for transfection efﬁciency it was found that the AKR/J
proximal promoter activity was reduced 30% relative to its
DBA/2J counterpart (p , 0.001) (Figure S3; Table S5) implying
a subtle functional difference in Rrp1b functionality between
the high and low metastatic genotypes.
Given the outcome of the promoter activity experiments,
we would expect to observe differential expression of Rrp1b
in tissue derived from the AKXD ancestral AKR/J and DBA/2J
strains. To test this hypothesis, we quantiﬁed expression of
Rrp1b in normal mammary tissue from AKR/J or DBA/2J
genotype mice. Following total RNA extraction from the
mammary tissue from three individual AKR/J mice and three
DBA/2J mice, reverse-transcription PCR (RT-PCR) was used
to synthesize cDNA, and Rrp1b expression determined using
qPCR. Rrp1b expression was found to be ;30% less in normal
mammary tissue derived from high metastatic potential AKR/
J mice compared to mammary tissue from the low metastatic
potential DBA/2J genotype (AKR/J normalized relative Rrp1b
quantity ¼ 1.21 6 0.20, DBA/2J relative expression ¼ 1.70 6
0.30; Mann Whitney U-test p ¼ 0.0495; Table S6). Combined,
the in vitro and in vivo data imply that germline poly-
morphism, in the form of proximal promoter polymorphism,
is causing differential functionality of Rrp1b in genetic
backgrounds of differential metastatic capacity.
A Gene Expression Signature Indicative of Ectopic
Expression of Rrp1b Predicts Survival in Human Breast
Cancer
If RRP1B is at least partially responsible for the presence of
the ECM components of metastasis predictive gene signa-
tures, it would suggest that a signature of RRP1B activation or
expression [20] might also be predictive of breast cancer
survival. To test this hypothesis, Affymetrix microarrays were
Table 1. Ectopic Expression of Rrp1b in the Highly Metastatic Mouse Mammary Tumor Cell Lines Mvt-1 and 4T1, and NIH-3T3 Mouse
Fibroblasts Modulates Expression of Various Metastasis Predictive ECM Genes
Gene Expression
Tested by qPCR
Mvt-1 4T1 NIH-3T3
Expression Ratio
Mvt-1/Rrp1b versus
Mvt-1/b-Gal
Standard
Deviation
Expression Ratio
4T1/Rrp1b versus
4T1/b-Gal
Standard
Deviation
Expression Ratio
NIH-3T3/Rrp1b
versus NIH-3T3
Standard
Deviation
Col1a1 2.54
a 1.05
a 0.09
a 0.06
a 0.61
a 0.20
a
Col1a2 1.33 0.80
bb 0.69
a 0.06
a
Col3a1 0.01
a 0.01
a 0.23
a 0.22
a 0.33
a 0.37
a
Col5a3
bb b b b b
Col6a2 0.05
a 0.04
a 1.20 0.77 0.75
a 0.11
a
Fbn1 0.71
a 0.15
a 0.53
a 0.10
a 0.49
a 0.02
a
Fbln2 0.08
a 0.02
a 0.48
a 0.35
a 1.61
a 0.37
a
Mfap5 0.09
a 0.03
a 0.33
a 0.15
a 0.02
a , 0.01
a
Mmp2
bb b b b b
Nid1 1.39 0.29
bb 0.79
a 0.02
a
Serpinf1 0.35
a 0.12
a 0.19
a 0.16
a 0.97 0.04
Serping1 0.02
a 0.02
a 7.23 5.23 0.18
a 0.07
a
Expression of each ECM gene was quantified in Mvt-1 cells by comparing ECM expression in four clonal isolates ectopically expressing Rrp1b and two Mvt-1 isolates ectopically expressing
b-galactosidase. In 4T1 cells, ECM expression was compared in three clonal isolates ectopically expressing Rrp1b and three 4T1 isolates ectopically expressing b-galactosidase. Finally, in
NIH-3T3 cells by comparing ECM gene expression in replicate RT-PCR reactions performed with total RNA isolated from either an Rrp1b-ectopically expressing or untransfected cell lines.
The table shows the average expression ratio across the four Mvt-1 Rrp1b clonal isolates or the replicate NIH-3T3 RT-PCRs. Mann-Whitney U-tests were performed to compare expression
of ECM genes between Rrp1b-transfected and control cell lines.
aStatistically significant at the p   0.05 level (bold typeface).
bECM gene expression too low to quantify in this cell line.
doi:10.1371/journal.pgen.0030214.t001
represent LRS for elevated transcription in mice with the AKR/J allele. The strongest degree of linkage is observed with the chromosome 17 eQTL, as
illustrated in the three QTL scans on the right. In total, nine of the 16 metastasis-predictive probes displayed a LRS that was at least suggestive of
linkage (denoted by the warm hues on the heat map to the left) suggesting that their expression is controlled in some respect by the chromosome 17
locus. These probes are located within the metastasis-predictive ECM genes Serping1, Nid1, Col1a1, Col1a2, Col3a1, Fbn1, and Mmp2. Rrp1b lies in very
close physical proximity to the peak LRS within the chromosome 17 locus and displays a high degree of correlation of expression with a number of
class-predictive ECM genes.
doi:10.1371/journal.pgen.0030214.g002
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isolates and three Mvt-1/b-galactosidase clonal isolates. An
Rrp1b expression signature was identiﬁed using the Class
Comparison tool of BRB ArrayTools was performed, using a
two-sample t-test with random variance univariate test. p-
Values for signiﬁcance were computed based on 10,000
random permutations, at a nominal signiﬁcance level of each
univariate test of 0.0001. A total of 1,739 probe sets
representing 1,346 genes passed these conditions. Signiﬁ-
cantly upregulated and downregulated probes according to
these criteria are listed in Tables S7 & S8, respectively.
A human RRP1B gene expression signature was generated
by mapping the differentially regulated genes from mouse
array data to human Rosetta probe set annotations [10]. One
hundred ninety six genes from the mouse data could be
mapped to the available Rosetta Hu25K chip annotations.
The 295 samples of the Rosetta data set [10] were clustered
into one of two groups representing high and low levels of
RRP1B activation in primary tumor samples in an unsuper-
vised manner based on the 196 signiﬁcantly differentially
expressed RRP1B signature genes on the Hu25K chip.
Kaplan-Meier survival analysis was performed to investigate
Figure 3. Ectopic Expression of Rrp1b Reduces (A) Tumor Growth and (B) Metastasis Burden in the Highly Metastatic Mvt-1 Cell Line
Mvt-1 cell lines were stably transfected with a mammalian expression vector encoding either Rrp1b or b-galactosidase. Following isolation of individual
clones by serial dilution and confirmation of ectopic gene expression, clonal isolates were subcutaneously implanted in FVB/NJ mice. Those mice
implanted with Mvt-1 clones ectopically expressing Rrp1b developed smaller primary tumors and fewer pulmonary metastases compared to mice
implanted with a clonal isolate ectopically expressing b-galactosidase.
doi:10.1371/journal.pgen.0030214.g003
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Rrp1b Modulates Cancer Progression and Metastasiswhether there was a survival difference between groups. A
signiﬁcant survival difference was observed implying that the
level of activation of RRP1B or RRP1B-associated pathways
within a tumor, presumably because of either somatic
mutation or germline polymorphism, may be an important
determinant of the overall likelihood of relapse and/or
survival (Figure 4A). Further analysis indicated that survival
was associated primarily because of the effects of 33 genes
(Table S9). The degree of survival difference represented by
the 33-gene RRP1B-induced gene expression signature was
similar to the original 70-gene signature described by van’t
Veer and colleagues [10] (Figure 4B).
Patient samples were stratiﬁed by estrogen receptor (ER)
and lymph node (LN) status, two clinically relevant prognos-
tic markers, to determine whether the RRP1B signature
might provide additional clinical stratiﬁcation. Expression of
the RRP1B signature in bulk primary tumor tissue predicted
outcome in patients that were both LN negative and LN
positive and patients with ER positive tumors (Figure 4C, 4D
& 4E, respectively). Patients with ER negative tumors did not
show a signiﬁcant survival beneﬁt (Figure 4F). However, this
may be due to the limited sample size and needs to be
clariﬁed with additional studies.
A Polymorphism in Human RRP1B Is Associated with
Improved Outcome: Orange County Cohort
To validate a possible role of RRP1B in human cancer, a
case-only pilot breast cancer association study was performed
to assess the role of a nonsynonymous SNP within the human
homolog of Rrp1b (dbSNP ID: rs9306160; 1421G!A, Pro436-
Leu) in human disease (Table S10). The variant A allele
frequency in this Caucasian cohort was 0.362 (n ¼ 269).
Univariate analysis revealed a signiﬁcant difference with
respect to disease stage (localized versus nonlocalized p ¼
0.006; Table 2). Of the 130 patients with localized disease at
diagnosis, 85 (65%) were carriers of the variant allele
compared with 74 of 139 (53%) of those with advanced
regional or metastatic disease. Signiﬁcant associations were
also observed with tumor ER and progesterone receptor (PR)
status, the presence of LN disease, and primary tumor grade.
The variant allele was more frequent among patients with ER
positive and PR positive primary tumors: 122 of 190
individuals (64%) with ER positive tumors had the variant
allele versus 25 of 54 patients (46%) with ER negative tumors
(p¼0.001), and 104 of 160 individuals (65%) with PR positive
tumors versus 41 of 82 subjects (50%) of those with PR
negative tumors (p ¼ 0.001). Furthermore, the AG and AA
genotypes were more frequent among patients with well to
moderately differentiated tumors (76 of 116 individuals (66%)
versus 49 of 96 subjects (51%) with poorly differentiated
tumors; p ¼ 0.001). The variant allele was also more frequent
among LN negative patients when compared with LN positive
patients (81 of 125 patients (65%) with no positive LN versus
65 of 123 individuals (53%) with  1 LN; p ¼ 0.033). No
signiﬁcant differences were observed with respect to primary
tumor size and variant allele status did not inﬂuence disease-
free survival in this cohort. Multivariate analysis that included
age at diagnosis as covariate conﬁrmed these results (Table 2),
which again demonstrated that the variant allele was
associated with a number of indicators of improved outcome.
Analysis in a Breast Cancer Cohort from the Greater
Baltimore Area
RRP1B SNP analysis was performed in a second small pilot
cohort consisting of 248 surgical breast cancer patients (58%
African-American, 42% Caucasian) from the greater Balti-
more area (Table S11) to attempt to replicate the ﬁndings of
the initial cohort study. Stratiﬁcation on race/ethnicity and
age at disease onset in the Baltimore cohort indicated that
neither of these variables was a signiﬁcant confounding
factor. Consistent with the Orange County cohort, the variant
A allele was less frequent in patients with a high stage or poor
grade tumor, with ER negative or PR negative tumors, and
with a LN positive disease (Table 3). Most associations
between the A allele and tumor markers were best explained
by assuming an additive effect of the variant allele (Tables 2 &
3), however, studies in larger populations are required to
better deﬁne the relative effect of the variant allele on
outcome markers in breast cancer. We also examined the
association between the 1421G!A SNP and breast cancer
survival by assuming a dominant effect of the variant allele on
survival, a model that best reﬂects our survival data. Carriers
of the variant allele had a signiﬁcantly better breast cancer-
speciﬁc survival compared to homozygous carriers of the
common allele (Figure 5). Multivariate Cox regression
analysis with adjustments for age at diagnosis, race, ER status,
tumor–node–metastasis (TNM) stage, and chemotherapy,
further conﬁrmed this observation. Patients who carried the
variant allele had improved survival when compared to
patients with the G/G genotype (hazard ratio of death (HR) ¼
0.46; 95% conﬁdence interval (CI) ¼ 0.21–0.97). This effect
was stronger among patients with an ER positive tumor (HR¼
0.17; 95% CI ¼ 0.04–0.70) suggesting that RRP1B may have a
particular function in the ER pathway.
Haplotype Analysis of the RRP1B Pro436Leu Variant
The Pro436Leu SNP was selected for analysis in the pilot
epidemiology analysis due to its potential effect on RRP1B
function as the result of the nonsynonymous amino acid
Figure 4. The RRP1B Microarray Expression Signature Predicts Survival into Good and Poor Outcome Groups Based on Tumor Gene Expression
(A) The RRP1B signature was highly predictive of overall survival in the Dutch Rosetta dataset, with the cumulative proportion survival being estimated
to be 72% versus 34% for the good and poor prognosis RRP1B signatures, respectively (RRP1B signature HR ¼ 3.28, 95% CI ¼ 2.11–5.11). (B) Indeed, it
appears that the RRP1B signature possesses a similar ability to predict survival in this dataset than the 70-gene signature described by van’t Veer et al.
[10]. Specifically, the survival for the good and poor prognosis 70-gene signatures were estimated to be 73% versus 47%, respectively (70 gene
signature HR ¼ 4.49, 95% CI ¼ 2.65–7.61). (C) To stratify patients more adequately based upon their disease characteristics, RRP1B signature gene
expression was examined with respect to tumor LN and ER status. Overall survival in the Dutch Rosetta patients with negative LNs was 79% versus 30%
for the good and poor prognosis RRP1B signatures, respectively (HR ¼ 4.34, 95% CI ¼ 2.36–7.99). (D) Similarly, the RRP1B signature could sub-stratify
patients with positive LNs into good and poor prognosis groups, with survivals being 65% versus 37%, respectively (HR¼2.38, 95% CI¼1.22–4.62). (E) A
similar stratification effect by tumor RRP1B signature gene expression was observed in patients with ER positive tumors, with an overall survival in
patients with ER positive tumors being 72% versus 50% for the good and poor prognosis RRP1B signatures, respectively (HR¼2.36, 95% CI¼1.17–4.77).
(F) However, it did not prove possible to stratify patients with ER negative tumors based upon their RRP1B expression signature. This likely reflects the
lack of individuals with this disease subtype in this cohort.
doi:10.1371/journal.pgen.0030214.g004
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Rrp1b Modulates Cancer Progression and Metastasissubstitution. The pilot epidemiology data, while consistent
with the possibility of role of RRP1B in breast cancer
progression, does not distinguish between causal polymor-
phisms and polymorphisms in high linkage disequilibrium
(LD) with the causal variant. To gain a better understanding
of whether the Pro436Leu SNP might be the causal variant
effecting RRP1B function, haplotype analysis was performed
using the publicly available HapMap data (http://www.
hapmap.org/downloads/index.html.en). rs9306160 was geno-
typed on the 30 CEPH trios (90 samples) used in the HapMap
project and the linkage disequilibrium (LD) structure
determined. Analysis of the current version of the HapMap
revealed that the Pro436Leu SNP was in a large haplotype
block spanning 212,658 bp, with 40 SNPs in high LD with
rs9306160 (r
2 . 0.8). The haplotype block encompasses only
two genes, RRP1B and HSF2BP. Among the 673 SNPs in this
region rs9306160 is the only missense polymorphism within
this haplotype block based on RefSeq annotation (http://www.
ncbi.nlm.nih.gov/RefSeq/), and therefore remains an interest-
ing candidate for the causative polymorphism. However, we
cannot exclude at this time the possibility that the causative
effect is due to a different linked polymorphism. Further
analysis at the epidemiology and molecular level will be
required to resolve this question.
Discussion
The diverse techniques employed in this study, including
genetical genomics [21], functional genomics, sequence
analysis, and molecular epidemiology, have allowed us to
identify Rrp1b as a candidate for both a tumor progression
and metastasis modiﬁer in mice, and a marker of inherited
breast cancer metastasis susceptibility in humans. Further-
more, functional data provides evidence that Rrp1b regulates
ECM gene expression, and that a nonsynonymous SNP in
RRP1B is associated with tumor progression and disease-
speciﬁc survival in pilot epidemiology experiments.
Rrp1b was identiﬁed through two distinct experimental
approaches designed to address two independent questions:
(a) what is the molecular mechanism(s) by which Sipa1
modulates metastasis, and (b) what drives ECM dysregulation
in metastasis-prone primary tumors? Yeast two-hybrid assays
and functional genomic studies addressed the ﬁrst question,
which identiﬁed Rrp1b as binding to the polymorphic PDZ
domain of Sipa1. The second question probed the origins of
metastasis-predictive gene expression signatures. ECM genes
are components of all metastasis-predictive gene expression
signatures in both humans [9–11,22] and mice [12,13], a
ﬁnding that may well be explained in part by constitutional
variation [13]. To test this question, we examined whether
ECM eQTLs and metastasis modiﬁers might be the same
entities by analyzing ECM gene expression in a RI mouse
panel. This led to the identiﬁcation of several eQTLs, with a
locus on proximal chromosome 17 displaying the strongest
linkage. The peak linkage region of this locus encompasses
both Rrp1b and a tumor growth and progression QTL [6], and
rather remarkably, when we examined expression of tran-
scripts within the peak eQTL linkage region, Rrp1b was highly
correlated with metastasis-predictive ECM gene expression.
Taken together, these data suggest that Rrp1b is a potential
dual ECM and tumor progression candidate.
Further experimentation demonstrated that ectopic ex-
pression of Rrp1b in two highly metastatic mammary tumor
cell lines and a mouse ﬁbroblast cell line modulates ECM gene
expression, a ﬁnding concurrent with our initial hypothesis
that Rrp1b is indeed the chromosome 17 ECM eQTL. It
should be noted however, that the directionality of the ECM
expression changes observed in response to Rrp1b activation
in these cell lines are not directly comparable to the changes
in ECM expression observed in metastasis-predictive gene
expression signatures [9–13]. Primary tumors are composed
of a variety of cell and tissue types, and this cellular and
microenvironmental heterogeneity is not accurately reﬂected
by in vitro growth conditions of single cell types. Never-
theless, we do argue that our in vitro experimentation
demonstrates that Rrp1b modulates the expression of meta-
stasis-predictive ECM genes in a variety of individual cell
lines. It is also evident that further work will be necessary to
deﬁne the complex microenvironmental relationships that
modulate ECM gene expression in bulk tumor tissue and their
relationship to overall levels of Rrp1b activation.
Table 3. Association of Tumor Characteristics with the RRP1B 1421G!A SNP in the Baltimore Cohort
Disease Characteristic RRP1B 1421G!A Genotype Multivariate Comparison of Genotype Frequencies
GG GA AA AG versus GG
a AA versus GG
a AG or AA versus GG
b
n % n % n %O R
c 95% CI p- Value OR
c 95% CI p- Value OR
c 95% CI p- Value
TNM Stage Low 103 58% 60 34% 16 9% 1.00 1.00 1.00
High 33 75% 9 21% 2 5% 0.46 0.21–1.04 0.061 0.41 0.09–1.91 0.260 0.45 0.21–0.94 0.037
ER Status Positive 81 57% 45 32% 15 11% 1.00 1.00 1.00
Negative 68 68% 28 28% 4 4% 0.72 0.40–1.28 0.270 0.34 0.11–1.12 0.076 0.63 0.36–1.09 0.096
PR Status Positive 47 53% 29 33% 12 14% 1.00 1.00 1.00
Negative 72 67% 32 30% 4 4% 0.72 0.39–1.35 0.310 0.22 0.07–0.75 0.015 0.57 0.32–1.03 0.062
Grade Well 60 57% 33 31% 12 12% 1.00 1.00 1.00
Poor 71 68% 29 28% 5 5% 0.72 0.39–1.34 0.300 0.39 0.13–1.19 0.100 0.64 0.36–1.14 0.130
Nodes No Positive Nodes 81 58% 43 31% 16 12% 1.00 1.00 1.00
  1 Positive Node 57 67% 26 31% 2 2% 0.86 0.47–1.55 0.610 0.19 0.04–0.85 0.030 0.67 0.38–1.18 0.170
aAnalysis of AG and AA compared to GG in logistic regression adjusted for age at diagnosis
bAnalysis of AG or AA compared to GG in logistic regression adjusted for age at diagnosis
cOdds ratio (OR) and the 95% confidence interval (CI)
doi:10.1371/journal.pgen.0030214.t003
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Rrp1b Modulates Cancer Progression and MetastasisIn addition, it should be noted that eQTL analysis is most
commonly associated with expression changes in normal
tissues, and not the neoplastic tissues analyzed in this study.
However, eQTLs owe their existence to germline polymor-
phism, and such variation will be present in tumor tissue in
addition to normal tissues. With this in mind, it is therefore
not unreasonable to assume that the phenotypic effects of
eQTLs will be observed in tumors as well as normal tissue. Yet
neoplastic tissues possess an inherent genomic instability, and
it is therefore possible that variations in tumor gene
expression patterns could also arise from somatic mutation.
However, we have demonstrated that eQTLs can be genet-
ically mapped in tumors, which suggests either that similar
somatic mutations consistently occur in the majority of the
tumor tissue in a subset of the RI strains, or that the observed
eQTLs result from inherited polymorphisms. Our previous
demonstration that the same ECM genes used to deﬁne tumor
eQTLs are differentially expressed in normal mammary
tissues derived from high- and low-metastatic mouse geno-
types [13] suggests that such differential expression may be
partially regulated by germline polymorphism. At this stage,
however, we cannot formally dismiss a role for somatic
mutation in ECM gene expression variation within RI
mammary tumors.
We also described a number of important functional
differences in Rrp1b between the progenitors of the AKXD
RI panel, the high metastatic AKR/J, and low metastatic DBA/
2J genotype mice. Speciﬁcally, the proximal promoter of
Rrp1b in AKR/J mice contained polymorphisms that may
reduce Rrp1b expression. This difference in promoter activity
is one possible explanation for the observed differences in
Rrp1b expression in the normal mammary tissue of these
mice, with the high metastatic capacity AKR/J mouse having
signiﬁcantly lower levels of Rrp1b activity than the low
metastatic DBA/2J mouse. Furthermore, ectopic expression
led to reduced metastatic potential and primary tumor
growth following tumor cell implantation into mice. In
combination, these observations suggest, at least in this
mouse model that increased Rrp1b expression correlate with a
better outcome.
We have used a dual approach to try to address the
importance of RRP1B in human breast cancer progression.
The ﬁrst of these approaches was to use data derived from
microarray expression analysis of the Mvt-1/Rrp1b cells to
address one of the central goals of our research: the
translation of experimental data from mouse models of
human breast cancer into potentially clinically relevant
observations. Based on the work of Bild et al. [20] we
identiﬁed an RRP1B gene expression signature and demon-
strated it that predicts outcome in a publicly available and
well-characterized breast cancer cohort [10]. This gene
signature not only held strong prognostic value in the Dutch
study cohort [10], but was also able to stratify those patients
with ER positive tumors and LN negative disease at
presentation into high and low risk categories. There has
been signiﬁcant interest in using gene expression proﬁles for
improved patient stratiﬁcation [23,24] in the clinic since it
raises the possibility of improvements in breast cancer
subtype classiﬁcation, which in turn could enable clinicians
to tailor treatment to individual patients. Whether the RRP1B
signature proves of clinical value in this respect is at present
unclear, and further testing of its prognostic value in different
cohorts will be required to address this possibility. The
signiﬁcance of this study, however, is not the identiﬁcation of
yet another prognostic signature, but the fact that the
underlying casual element is known. Identiﬁcation of other
genetic elements that drive the predictive gene expression
patterns may provide a more robust means of complementing
currently available tests used for the assessment of prognosis
in breast cancer. Furthermore, this type of study also provides
us with potentially novel and important insights into the
mechanisms underlying the metastatic process.
Further supportive evidence for the role of RRP1B in
human breast cancer progression was evident in the two pilot
epidemiological studies, both of which found an inverse
relationship between the variant A allele of the 1421G!A
RRP1B SNP and poor outcome markers. These consistent
ﬁndings indicate that 1421G!A is a marker for disease
progression, and patients who carry the A allele are less likely
to present with advanced disease than homozygous carriers of
the more common G allele. These data are consistent with the
results of functional analysis of Rrp1b, and associate RRP1B
with disease outcome in human breast cancer. It should be
noted that the variant 1421G!A allele was associated with
improved outcome in those individuals with ER positive
tumors, which may permit better stratiﬁcation of patients
who are currently thought to be in a low risk category. A
particularly intriguing question is if and how a patient’s
1421G!A genotype affects expression of the 33-gene RRP1B
expression signature, and whether polymorphisms in the
promoter of RRP1B in linkage disequilibrium with the
1421G!A SNP are more important in this respect. These
studies are currently ongoing in this laboratory. Indeed, a link
between constitutional polymorphism and bulk tumor gene
expression would be particularly signiﬁcant given the
technical difﬁculties associated with tumor gene expression
proﬁling and the relative ease of SNP genotyping. These
results, while consistent between the studies and in support of
our hypothesis, must be considered only as preliminary.
Further investigations in larger epidemiology studies specif-
ically designed to address tumor progression and outcome,
rather than tumor incidence, will be necessary to gain further
Figure 5. RRP1B 1421G!A SNP and Breast Cancer Survival
Kaplan-Meier survival analysis. The survival of patients with the variant
allele (A/G or A/A; n ¼ 92) is significantly better than the survival of
patients who are homozygous carriers of the common allele (G/G; n ¼
150). Two-sided log-rank test: p ¼ 0.025.
doi:10.1371/journal.pgen.0030214.g005
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Rrp1b Modulates Cancer Progression and Metastasissupport for the role of germline polymorphism in RRP1B in
breast cancer progression.
Several differences were evident between the epidemiology
study cohorts, the most notable of which was that the
1421G!A SNP was associated with breast cancer-speciﬁc
survival only in the Baltimore cohort, a discrepancy that is
likely due to several factors. First, both cohorts are relatively
small (n , 300), thus some differences might arise from
statistical power issues. More importantly, the study popula-
tion compositions differed: the Orange County cohort was
derived from a population-based case-cohort study, including
all cancer patients, regardless of stage, with more than 10
years of follow up, whereas the Baltimore cohort is a surgical
breast cancer population, and therefore is biased against
patients with metastatic disease at presentation. Further-
more, unlike the Orange County cohort, the Baltimore cohort
contained African-American and Caucasian women. Differ-
ences in race/ethnicity inﬂuence allele frequency and disease
outcome, and some variabilit yi nr e s u l t si st h e r e f o r e
expected. While the participation of patients from different
race/ethnicities also strengthens study design, stratiﬁcation is
required. Stratiﬁcation on race/ethnicity in the Baltimore
cohort indicated that race/ethnicity was not a signiﬁcant
confounding factor. It is interesting to note, however, that the
variant allele distribution is different in African-Americans
and Caucasians in the Greater Baltimore cohort (0.099 in
African-Americans versus 0.411 in Caucasians). It is known
that African-American women have a poorer prognosis
compared to other breast cancer patients [25], and given
the protective effect exerted by the variant 1421G!A, it is
interesting to speculate that polymorphisms in genes such as
RRP1B may be driving these ethnicity-speciﬁc differences in
outcome. Thus, further characterization of this SNP in larger
and ethnically diverse cohorts is required to determine the
inﬂuence of race/ethnicity upon the association between this
SNP and breast cancer survival.
The function of Rrp1b and its exact role in metastasis
remain unclear at this time. Sipa1 was originally cloned as a
mitogen-inducible protein [26] that was subsequently shown
to be a negative regulator of Rap1 by serving as a GAP for
Rap1 [27]. Sipa1 has signiﬁcant effects on cellular adhesion
[28], primarily related to its effects on Rap1, which has been
implicated in maintaining the integrity of polarized epithelia
[29] and intercellular adherens junctions [30], and potentially
integrating signaling between cadherins and integrins [31].
Rrp1b may therefore mediate tumor cell adhesion properties
by altering intercellular and cell–ECM contacts in a Sipa1-
dependent and Rap1-dependent manner. It should be noted,
however, that the human polymorphism in RRP1B falls
outside of the domain that directly interacts with the PDZ
domain of Sipa1. Whether this polymorphism impacts the
enzymatic function of Sipa1 or mediates metastatic potential
through some other mechanism is unclear and currently
under investigation. Similarly, it is unclear whether the amino
acid substitution in human RRP1B directly affects function.
Based on the mouse model, where increased expression
confers protection against malignant progression, the variant
leucine in the human ortholog may phenocopy the mouse
situation by activating some function of RRP1B. Further in
v i t r oa n a l y s i sw i l lb er e q u i r e dt oc l a r i f yt h ed i f f e r e n t
situations in the two species and is currently under inves-
tigation in our laboratory.
In addition to the negative regulatory role on Sipa1
function, there is some evidence to suggest that Rrp1b may
be involved in RNA metabolism. Protein homology analysis
has shown Rrp1b to contain a Nop52 domain, a motif found in
proteins critical to 28S rRNA generation [32], and a previous
yeast two-hybrid analysis has shown that Rrp1b may also
interact with Lsm1, which is a protein involved in regulation
of mRNA degradation [33]. Publicly available databases show
that RRP1B is ubiquitously expressed at a somewhat low level,
although it is expressed at a slightly higher level in lymph
nodes in humans (http://smd.stanford.edu/cgi-bin/source/
sourceSearch). Differential expression of RRP1B has been
reported in ﬁbroblasts from patients with systemic sclerosis,
an autoimmune disorder characterized by dysregulation of a
variety of ECM genes, including procollagens I, III, and VI [34],
consistent with our results. Further research, however, is
clearly needed to fully explore the role of Rrp1b and Sipa1 in
human breast cancer and other tumor types. Unraveling the
mechanisms of action and the molecular pathways that they
regulate are likely to provide novel and valuable insights into
tumor dissemination and metastasis.
Materials and Methods
Yeast two-hybrid analysis. Yeast two-hybrid screens using different
regions of the human Sipa1 protein (Entrez Gene ID No: 6494) as bait
were performed by ProNet technology (Myriad Genetics, Salt Lake
City, UT). Methodology for these commercially performed experi-
ments is provided by Myriad Genetics and is available in Text S2.
Coimmunoprecipitation of Rrp1b with Sipa1. The various genes
were cloned into pcDNA3. HEK293 (293) cells were transiently
transfected with lipofectamine (Invitrogen) according to the manu-
facturer’s instructions. They were cotransfected with pcDNA3 vector
or mouse Sipa1-V5 from DBA [7], and Rrp1b-V5, Rrp1b-HA, or AQP2
(from American Type Culture Collection). Two days after trans-
fection, cells were lysed with Golden Lysis Buffer (GLB) containing 20
mM Tris (pH 7.9), 137 mM NaCl, 5 mM EDTA, 1 mM EGTA, 10 mM
NaF, 10% Glycerol, 1% Triton X-100, 1 mM sodium pyrophosphate, 1
mM leupeptin, 1 mM PMSF, and aprotinin (10 lg/ml). Cell extracts
were immunoprecipitated with anti-Spa-1 (Sipa1) mAb (BD Bio-
Sciences), and protein A/G Sepharose (Pierce) were added and rotated
overnight at 4 8C. The immune complexes were washed once with
GLB, once with high salt HNTG (20 mM Hepes, 500 mM NaCl, 0.1%
Triton X-100, 10% Glycerol), and twice with low salt of HNTG (20 mM
Hepes, 150 mM NaCl, 0.1% Triton X-100, 10% Glycerol). The immune
complexes were then analyzed by immunoblotting with antibodies
against AQP2 (Santa Cruz), V5 (Invitrogen), or HA (Convance). For
each immunoblot, horseradish peroxidase-conjugated anti-rabbit,
anti-mouse, or anti-goat immunoglobulin G was used for the second
reaction at a 1:10,000 dilution. Immunoblots were visualized by
enhanced chemiluminescence with an ECL Kit (Amersham).
RALGDS pull-down assay. 293 cells were transiently cotransfected
with pcDNA3 vector or mouse Sipa1 and Rrp1b-V5 or AQP2. Epac-
HA was also cotransfected, to elevate the level of Rap1-GTP, and
pcDNA3 vector was added as necessary to ensure that equal amounts
of DNA were transfected. Transfected cells were processed two days
later, using a Rap1 activation Kit (Upstate Biotech) according to the
manufacturer’s instructions. Equal amounts of the total protein from
cell extracts were estimated based on BCA protein assay kit (Pierce).
Rap1-GTP protein was pulled down by RalGDS-RBD beads and
washed three times, then subjected to gel analysis and immunoblot-
ting using anti-Rap1 antibody (Santa Cruz). Cell extracts from
transfectants were analyzed for protein expression by immunoblot-
ting, using anti-AQP2 antibody, anti-Spa-1 mAb, or anti-V5 antibody.
Cell culture. The Mvt-1 and 4T1 cell lines were obtained as a gift
from Lalage Wakeﬁeld (National Cancer Institute, Bethesda). The cells
were cultured in Dulbecco’s Modiﬁcation of Eagle’s Medium (DMEM;
Cellgro, VA) containing 10% fetal bovine serum (FBS; Cellgro, VA),
with culture medium being replaced at three day intervals. When the
cells achieved conﬂuency, they were washed once with 5 ml
phosphate-buffered saline (PBS), incubated with 2 ml trypsin-EDTA
for 5 min, and passaged at a 1:30 dilution into a fresh culture ﬂask.
NIH-3T3 cells were maintained in the same manner as Mvt-1, except
cells were passaged at a 1:15 ratio when they achieved conﬂuency.
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and generation of the microarray expression data from AKXD 3
PyMT primary tumors has been described previously [13]. Affymetrix
.CEL ﬁles were normalized using the RMA method, averaged for each
AKXD RI strain, and loaded into the GeneNetwork web service
(www.genenetwork.org) [15]. The database was then searched for the
11 probe sets from our previously described metastasis signature
proﬁle [13] classiﬁcation as within an ‘‘ECM component’’
(1437568_at, Mmp16; 1418454_at, Mfap5-pending; 1416168_at,
Serpinf1; 1425896_a_at, Fbn1; 1416625_at, Serping1; 1450798_at,
Tnxb; 1439364_a_at, Mmp2; 1427884_at, Col3a1; 1416808_at, Nid1;
1423407_a_at, Fbln2; and 1420924_at, Timp2). Additionally, a
further ﬁve probe sets for the ECM genes represented the human
breast carcinoma metastasis gene signature proﬁle described by
Ramaswamy et al. [9] were also included (Col1a1: 1423669_at_A,
1455494_at_A and Col1a2: 1423110_at_A, 1446326_at_B,
1450857_a_at_A). eQTLs were deﬁned as described above.
Development of Mvt-1 and 4T1 clonal isolates ectopically express-
ing Rrp1b. An expression vector encoding the full length Rrp1b cDNA
BC016569 in pCMV-SPORT6 was obtained from the Mammalian
Gene Collection (MGC:27793, IMAGE ID: 3157173). The control cell
line was generated using the vector pCMV-SPORT-b-Galactosidase
(Invitrogen). The identity of the vector was sequence veriﬁed before
transfection. Supercoiled plasmids were transfected into Mvt-1 and
4T1 cells using Superfect Transfection Reagent (Qiagen, Valencia,
CA) as per the manufacturer’s instructions. Brieﬂy, transfections were
performed in 100 mm diameter culture dishes, with 2 310
6 Mvt-1 or
4T1 cells being seeded 24 h prior to transfection. The Rrp1b-pCMV-
Sport6 and pCMV-SPORT-b-Galactosidase vectors were cotrans-
fected with the vector pSuper.Retro.Puro (Oligoengine) containing
no insert as a selectable marker for transfectants. Cells in each
culture vessel were transfected with a total of 20 lg vector DNA using
Superfect at a 6:1 lipid to DNA ratio. Twenty-four hours after
transfection, the cells were selected in normal growth medium
containing 10 lg/ml puromycin (Sigma Aldrich), transferred to 96
well plates, and individual clones were selected by limiting dilution.
Colonies were screened by qPCR as described below to identify clones
ectopically expressing Rrp1b.
With regards to the NIH-3T3 cell lines, PCR primers were designed
to encompass the entire length of the Rrp1b cDNA BC016569. The
following primer sequences generated a 2,248 bp product from
normal mammary tissue cDNA, with the downstream primer being
designed to omit the transcription termination codon and to remain
in coding frame: 59-CCCATACGCAGACGCAGT-39 and 59-GAA-
GAAGTCCGCAGCCCT-39. Full length Rrp1b cDNA was then ampli-
ﬁed using rTth DNA Polymerase, XL (Applied Biosystems) as per the
manufacturer’s protocol. Following PCR ampliﬁcation, Rrp1b cDNA
was inserted into the reporter vector pcDNA3.1 V5-His using a
pcDNA3.1 V5-His TOPOt Cloning Kit (Invitrogen) and transformed
into TOP10 competent cells (Invitrogen) as per the manufacturer’s
protocol. Plasmids were propagated in 100 ml LB Medium containing
100lg/ml ampicillin. Plasmid DNA was extracted using a Qiagen
EndoFree Maxi Kit, and insert identity and integrity of the full-length
sequence was veriﬁed prior to further experimentation. Transfection
of this vector into NIH-3T3 cells was performed in the same manner
as for Mvt-1 cells except that the Rrp1b construct was cotransfected
with the puromycin selection marker pPur (Clontech), and selection
of transformants performed using 5 lg/ml puromycin and 700 lg/ml
G418 (Sigma Aldrich).
Total RNA isolation for qPCR. Total RNA samples were isolated
from cell culture samples using an RNeasy Mini Kit (Qiagen) with
sample homogenization being performed using a 21 gauge needle and
syringe as per the manufacturer’s protocol. All samples were
subjected to on-column DNase digestion, and RNA quality and
quantity determined by an Agilent Technologies 2100 Bioanalyzer
(Bio Sizing Software version A.02.01, Agilent Technologies). Only
those samples containing high-quality total RNA with A260/A280 ratios
between 1.8 and 2.1 were used for further analysis.
Quantitative Real-Time PCR gene expression analysis. cDNA was
synthesized from RNA isolated from either primary tumor tissues or
transfected cell lines using the ThermoScript RT-PCR System
(Invitrogen, Carlsbad, CA) by following the manufacturer’s protocol.
Single RT-PCRs were performed for each Mvt-1 and 4T1 clonal
isolates, and in triplicate for the untransfected or Rrp1b-expressing
NIH-3T3 total RNAs. SYBR Green qPCR was performed to detect the
cDNA levels of Rrp1b and a variety of metastasis predictive ECM
genes (see above) using an ABI PRISM 7500 and/or 7900HT Sequence
Detection Systems and custom designed primers (Table S12).
Reactions were performed using QuantiTect SYBR Green Master
Mix (Qiagen, Valencia, CA) as per the manufacturer’s protocol. The
cDNA level of each gene was normalized to peptidylprolyl isomerase B
(Ppib) cDNA levels using custom-designed primers for SYBR green-
ampliﬁed target genes (Table S12).
Sequencing of the Rrp1b gene. Complete sequencing of the exons,
intron-exon boundaries, promoters, and the regions immediately
upstream of the promoters was performed in two highly metastatic
(AKR/J, FVB/NJ) and three low metastatic (DBA/2J, I/LnJ, NZB/B1NJ)
strains of mice [35]. The sequences of the primers for Rrp1b are
shown in Table S4. PCR products were generated under standard
ampliﬁcation conditions (5 min at 94 8C, 30 s at 57 8C, 30 s at 72 8C,
and 5 min at 72 8C), puriﬁed with a Qiagen PCR puriﬁcation kit, and
double strand sequencing performed with a Perkin Elmer BigDye
Terminator sequence kit. Analysis was performed on a Perkin Elmer
3100 Automated Fluorescent Sequencer. Sequences were compiled
and analyzed with the computer software package VectorNTI [36].
Generation of Rrp1b proximal promoter b-galactosidase reporter
constructs. PCR primers were designed to encompass the two proximal
promoter polymorphisms identiﬁed by sequencing Rrp1b. The follow-
ing primer sequences generated a 1,672 bp product with AKR/J
genomic DNA and a 1,670 bp product with DBA/2J: 59-AACCT-
CATCGTCCCTTGG-39 and 59-GCACTCGCTTCAGCATCC-39.P r o x -
imal promoter sequences were ampliﬁed using rTth DNA Polymerase,
XL (Applied Biosystems) as per the manufacturer’s protocol. Following
PCR ampliﬁcation, proximal promoter sequences were inserted into
the reporter vector pBlue TOPO using a pBlue TOPOt TA Expression
Kit (Invitrogen) and transformed into TOP10 competent cells
(Invitrogen) as per the manufacturer’s protocol. Plasmids were
propagated in 100 ml of Luria-Bertani Medium containing 100 lg/ml
ampicillin. Plasmid DNA was extracted using a Qiagen EndoFree Maxi
Kit. AKR/J and DBA/2J promoter constructs were sequence veriﬁed
prior to further experimentation as described above.
Quantiﬁcation of activity of Rrp1b proximal promoter b-galactosi-
dase reporter constructs. Supercoiled plasmids were transfected into
NIH-3T3 cells using Superfect Transfection Reagent (Qiagen,
Valencia, CA) as per the manufacturer’s instructions. Brieﬂy, trans-
fections were performed in 100 mm diameter culture dishes, with 23
10
6 NIH-3T3 cells seeded 24 h prior to transfection with 10lg vector
DNA (8lg Rrp1b promoter construct and 2lg of pGL3-Control
(Promega)) using Superfect at a 5:1 lipid to DNA ratio. Transfections
were performed in triplicate for each promoter construct. Twenty-
four hours after transfection, the cells were washed with PBS,
trypsinized, collected, and washed twice with cold PBS. Cell lysis was
achieved using 100 ll of lysis buffer per 100 ml plate from a b-
Galactosidase Assay Kit (Invitrogen). b-galactosidase activity in each
sample was assayed as per the manufacturer’s protocol using either 20
llo r3 0ll of the lysate. The remaining lysate was used to determine
lysate protein concentration, which was assayed using a BCA Assay
Kit (Pierce). b-galactosidase activity was calculated for each sample as
per the b-Galactosidase Assay Kit (Invitrogen), but is essentially based
upon the concentration and A562 of each lysate. These speciﬁc
activities were normalized against ﬁreﬂy luciferase activity as driven
by the pGL3 control vector to account for differing transfection
efﬁciencies. The activity of ﬁreﬂy luciferase for each sample was
assayed using a Dual-Luciferase Reporter Assay Kit (Promega) and
quantiﬁcation performed by VICTOR2 (Perkin-Elmer Life Sciences).
Quantiﬁcation of Rrp1b expression in normal mammary tissue.
Total RNA extractions from tissue samples were carried out using
TRIzol
t Reagent (Life Technologies, Inc.) according to the standard
protocol. RNA quantity and quality were determined by the Agilent
Technologies 2100 Bioanalyzer (Bio Sizing Software version A.02.01,
Agilent Technologies) and/or the GeneQuant Pro (Amersham
Biosciences). Samples containing high-quality total RNA with A260/
A280 ratios between 1.8 and 2.1 were puriﬁed with the RNeasy Mini
Kit (Qiagen). An on-column genomic DNA digestion was performed
as part of this puriﬁcation step using the RNase-Free DNase Kit
(Qiagen). TaqMan qPCR was performed to detect the cDNA levels of
Rrp1b using an ABI PRISM 7500 Sequence Detection System (Applied
Biosystems, Foster City, CA). Rrp1b expression was quantiﬁed using
the Applied Biosystems Assay-On-Demand Mm00551206_m1. The
housekeeping gene Peptidylprolyl Isomerase B (Ppib), used for normal-
ization of Rrp1b expression between samples, was quantiﬁed using the
primers described in Table S12 and the following ﬂuorogenic probe:
6FAM-TCTATGGTGAGCGCTTC-MGB. Reactions were performed
using TaqMan Universal PCR Mastermix (Applied Biosystems) per the
manufacturer’s protocol.
Spontaneous metastasis assays. Transfected cells proven to be
stably expressing Rrp1b were subcutaneously implanted into virgin
FVB/NJ mice. Two days before injection, cells were passaged and
permitted to grow to 80%–90% conﬂuence. The cells were then
washed with PBS and trypsinized, collected, washed twice with cold
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6 cells/ml.
One hundred thousand cells (100 ll) were injected subcutaneously in
the vicinity of the fourth mammary gland of 6-wk-old virgin FVB/NJ
female mice. The mice were then aged for 4 wk before they were
killed by anesthetic overdose. Tumors were dissected and weighed.
Lungs were isolated and surface metastases enumerated using a
dissecting microscope. Tumor growth and metastasis was compared
to mice injected with 10
5 Mvt-1 cells stably cotransfected with pCMV-
Sport-b-Gal and pSuper.Retro.Puro. These experiments were per-
formed in compliance with the National Cancer Institute’s Animal
Care and Use Committee guidelines.
SNP genotyping. The Rrp1b 1421G!A polymorphism was charac-
terized using SNP-speciﬁc PCR. PCR primers were designed using
Primer Express software (Applied Biosystems) according to param-
eters described elsewhere [37]. Each probe was labeled with a reporter
dye (either VIC
t, a proprietary ﬂuorescent dye produced by Applied
Biosystems, or FAM, 5-(&6)-carboxyﬂuorescein) speciﬁc for the wild-
type and variant alleles of the Rrp1b SNP. Sequences of PCR primers
are as follows: 59-TGGACGTGGCCTCTGCAC-39 and 59-CAC-
CACCTGCAGCCTGAAA-39; and the sequences of ﬂuorogenic probes
are as follows: 6FAM-AGGGCTTTCAGCCCAGAG and VIC-
AGGGCTTTCGGCCCAG. Reaction mixtures consisted of 300 nM
of each oligonucleotide primer, 100 nM ﬂuorogenic probes, 8 ng
template DNA, and 23 TaqMan Universal PCR Master Mix (Applied
Biosystems, Foster City, CA) in a total volume of 10 ll. The
ampliﬁcation reactions were performed in a MJ Research DNA
Engine thermocycler (Bio-Rad, Hercules, CA) with two initial hold
steps (50 8C for 2 min, followed by 95 8C for 10 min) and 50 cycles of a
two-step PCR (92 8C for 15 s, 60 8C for 1 min). The ﬂuorescence
intensity of each sample was measured post-PCR in an ABI Prism
7500 sequence detection system (Applied Biosystems, Foster City,
CA), and Rrp1b SNP genotypes were determined by the ﬂuorescence
ratio of the nucleotide-speciﬁc ﬂuorogenic probes.
RNA extraction and processing for Affymetrix GeneChip analysis
Total RNA was extracted using TRIzol Reagent (Life Technologies)
according to the standard protocol. Total RNA samples were
subjected to DNase I treatment, and sample quantity and quality
determined as described above. Puriﬁed total RNA for each clonal
isolate were then pooled to produce a uniform sample containing 8
lg of RNA.
Double stranded cDNA was synthesized from this preparation
using the SuperScript Choice System for cDNA Synthesis (Invitrogen)
according to the protocol for Affymetrix GeneChip Eukaryotic
Target Preparation. The double stranded cDNA was puriﬁed using
the GeneChip Sample Cleanup Module (Qiagen). Synthesis of biotin-
labeled cRNA was obtained by in vitro transcription of the puriﬁed
template cDNA using the Enzo BioArray High Yield RNA Transcript
Labeling Kit (T7) (Enzo Life Sciences). cRNAs were puriﬁed using the
GeneChip Sample Cleanup Module (Qiagen). Hybridization cocktails
from each fragmentation reaction were prepared according to the
Affymetrix GeneChip protocol. The hybridization cocktail was
applied to the Affymetrix GeneChip Mouse Genome 430 2.0 arrays,
processed on the Affymetrix Fluidics Station 400, and analyzed on an
Agilent GeneArray Scanner with Affymetrix Microarray Suite version
5.0.0.032 software. Normalization was performed using the BRB-
Array Tools software [38,39].
Microarray and survival analysis. To generate a high conﬁdence
human transcriptional signature of Rrp1b expression, 98 probe sets
whose differential expression demonstrated p , 10
 7 were selected by
matching the gene symbols from the mouse dataset to the published
Hu25K chip annotation ﬁles. Analysis of tumor gene expression from
breast cancer datasets was performed using BRB ArrayTools.
Expression data were downloaded from the Rosetta Company website
(http://www.rii.com/publications/2002/vantveer.html). Expression data
were loaded into BRB ArrayTools using the Affymetrix GeneChip
Probe Level Data option or the Data Import Wizard. Data were
ﬁltered to exclude any probe set that was not a component of the
Rrp1b signature, and to eliminate any probe set whose expression
variation across the data set was p   0.01.
Unsupervised clustering of each dataset was performed using the
Samples Only clustering option of BRB ArrayTools. Clustering was
performed using average linkage, the centered correlation metric and
center the genes analytical option. Samples were assigned into two
groups based on the ﬁrst bifurcation of the cluster dendogram, and
Kaplan-Meier survival analysis performed using the Survival module
of the software package Statistica. Signiﬁcance of survival analyses
was performed using the Cox F-test.
Breast cancer cohorts. Orange County, California. This patient
population is a random sample of 269 probands successfully
genotyped for the Rrp1b SNP that were diagnosed between March
1, 1994 and February 28, 1995 with invasive breast cancer. Probands
were ascertained through the population-based Hereditary Breast
Cancer Study funded by the National Cancer Institute. A description
of the study and details of data collection methods have been
reported previously [8,40]. Brieﬂy, there were two case groups: cases
with localized disease (n ¼ 130), and cases with regional/metastatic
disease (n¼139). The average age at diagnosis of this cohort was 55.9
6 13.4 years, and the average body mass index was 25.7 6 4.9.
Greater Baltimore, Maryland. Surgical breast cancer cases were
recruited at the University of Maryland Medical Center, the
Baltimore Veterans Affairs Medical Center, Union Memorial Hospi-
tal, Mercy Medical Center, and the Sinai Hospital in Baltimore,
Maryland between February 15, 1993 and August 27, 2003. We
collected blood, tissue specimens, and survival information from 248
patients. These patients had pathologically conﬁrmed breast cancer,
were of African-American or Caucasian descent by self-report, were
diagnosed with breast cancer within the last six months prior to
recruitment, and had, by self-report, no previous history of the
disease. Patients were excluded if they were HIV, hepatitis B virus, or
hepatitis C virus carriers, were intravenous drug users, were
institutionalized, or were physically or mentally unable to sign
consent and complete the questionnaire. Of the eligible patients that
were identiﬁed through surgery lists, 83% participated in the study.
The subjects signed a consent form and completed an interviewer-
administered questionnaire. Additional information to determine
the ER-a status, disease stage, treatment, and survival was obtained
from medical records and pathology reports, the Social Security
Death Index, and the National Death Index. Disease staging was
performed according to the TNM system of the American Joint
Committee on Cancer/ the Union Internationale Contre le Cancer
(AJCC/UICC). The Institutional Review Boards at the participating
institutions approved the study.
Statistical analysis. Student’s t-tests were used to compare means
for continuous variables and Wilcoxon’s sum rank test to compare
medians. Variables that were not normally distributed, such as tumor
size, were log transformed. Chi-square test or Fisher’s exact tests were
used to test for differences between categorical variables and to test
for Hardy-Weinberg equilibrium. Unconditional logistic regression
adjusting for multivariate covariates, such as age at diagnosis, was
used to estimate the adjusted odds ratios. We used likelihood ratio
tests to calculate p-values comparing a model with covariates to a
model without them. We used Cox regression models to perform
survival analysis. All p-values presented are two-tailed and were
considered to be statistically signiﬁcant if they were below 0.05. The
Kaplan-Meier method and the log-rank test were used for univariate
survival analysis and Cox regression models were used to perform
multivariate survival analysis. For the Baltimore cohort, survival was
determined for the period from the date of hospital admission to the
date of the last completed search for death entries in the Social
Security Index (August 18, 2004) for the 248 case patients. The mean
follow-up time for breast cancer survival was 55 months (range: 12 to
140 months). A total of 59 (24%) of these 248 patients died during
this period. We obtained death certiﬁcates of the deceased case
patients and censored all causes of death that were not related to
breast cancer, such as accidents, violent crimes, stroke, heart attack,
and liver cirrhosis, in our analysis.
Haplotype analysis. The genotype data of the 90 HapMap CEPH
trio in the 250 kb ﬂanking region of rs9306160 was downloaded from
the HapMap database (http://www.hapmap.org). A total of 304 SNPs
with minor allele frequency  10% were selected to evaluate the LD
structure. The CEPH genotype data we generated for rs9306160 were
integrated with the HapMap data in this analysis. Using LDSelect [41]
with a cut of r
2   0.64 we found a large LD block spanning a 210 kb
genomic region (chr21:43739961–43952618) that has 104 SNPs in
high LD with rs9306160 (Figure 6). In this 210 kb region, there are a
total of 673 dbSNP markers and rs9306160 is the only nonsysnon-
ymous SNP based on RefSeq annotation.
Supporting Information
Figure S1. Chromosome 17 ECM eQTL Locus in AKXD RI Mice
ECM eQTL analysis in AKXD mice revealed that a locus on proximal
chromosome 17 inﬂuenced the expression of metastasis-predictive
ECM genes. The chromosome 17 locus peak linkage region (;29.5
Mb) colocalizes with a previously described metastasis efﬁciency and
tumor growth kinetics QTL [6], and encompasses the physical
location of Rrp1b (;29.9 Mb).
Found at doi:10.1371/journal.pgen.0030214.sg001 (255 KB PDF).
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Ectopic expression of Rrp1b does not alter the growth kinetics of the
Mvt-1 cell line.
Found at doi:10.1371/journal.pgen.0030214.sg002 (265 KB PDF).
Figure S3. Strain-Speciﬁc Variation in Rrp1b Promoter Activity
Promoter activity assays reveal that Rrp1b proximal promoter activity
was reduced 30% in AKR/J genotype relative to its DBA/2J counter-
part (p , 0.001).
Found at doi:10.1371/journal.pgen.0030214.sg003 (276 KB PDF).
Table S1. Baits Represented in Yeast-Two Hybrid SIPA1 Interaction
Analysis
Found at doi:10.1371/journal.pgen.0030214.st001 (16 KB XLS).
Table S2. Proteins Interacting With SIPA1 on Yeast-Two Hybrid
Interaction Analysis
Found at doi:10.1371/journal.pgen.0030214.st002 (19 KB XLS).
Table S3. Genes with Expression Associated with Metastasis-Predic-
tive ECM Genes on eQTL Analysis: Chromosome 17 Locus
Found at doi:10.1371/journal.pgen.0030214.st003 (47 KB XLS).
Table S4. Rrp1b Sequencing Amplicons: Primers and Polymorphisms
Found at doi:10.1371/journal.pgen.0030214.st004 (25 KB XLS).
Table S5. Promoter Activity Assays for AKR/J and DBA/2J Proximal
Rrp1b Promoters
Found at doi:10.1371/journal.pgen.0030214.st005 (30 KB XLS).
Table S6. qPCR Analysis of Rrp1b Expression in the Normal
Mammary Tissue of AKR/J and DBA/2J Mice
Found at doi:10.1371/journal.pgen.0030214.st006 (21 KB XLS).
Table S7. Genes Upregulated by Ectopic Expression of Rrp1b in Mvt-
1 Cells
Found at doi:10.1371/journal.pgen.0030214.st007 (142 KB XLS).
Table S8. Genes Downregulated by Ectopic Expression of Rrp1b in
Mvt-1 Cells
Found at doi:10.1371/journal.pgen.0030214.st008 (181 KB XLS).
Table S9. Hazard Ratio for Genes Associated With Survival
Found at doi:10.1371/journal.pgen.0030214.st009 (17 KB XLS).
Table S10. Characteristics of the Orange County Breast Cancer
Cohort
Found at doi:10.1371/journal.pgen.0030214.st010 (18 KB XLS).
Table S11. Characteristics of the Greater Baltimore Breast Cancer
Cohort
Found at doi:10.1371/journal.pgen.0030214.st011 (18 KB XLS).
Table S12. Quantitative RT-PCR Primer Sequences
Found at doi:10.1371/journal.pgen.0030214.st012 (19 KB XLS).
Text S1. Supplementary Data
A detailed explanation and discussion of the ECM eQTL data.
Found at doi:10.1371/journal.pgen.0030214.sd001 (76 KB DOC).
Text S2. Supplementary Methods
Found at doi:10.1371/journal.pgen.0030214.sd002 (62 KB PDF).
Accession Numbers
Accession numbers for genes mentioned in this paper from the
Mammalian Gene Collection (http://mgc.nci.nih.gov/) are Rrp1b cDNA
BC016569 (MGC:27793, IMAGE ID: 3157173).
Accession numbers for genes mentioned in this paper from the
Entrez Gene database (http://www.ncbi.nlm.nih.gov/sites/
Figure 6. Haplotype Structure Surrounding rs9306160 in the CEPH Families
The LD structure of rs9306160. Pairwise r
2 values are shown with gray scale; the higher the r
2 value the darker the color. The red line and arrow mark the
location of rs9306160. The large block in the middle represents the 210 kb LD block where 104 SNPs are in high LD with rs9306160. The figure was
generated by the program HaploView [42].
doi:10.1371/journal.pgen.0030214.g006
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Rrp1b Modulates Cancer Progression and Metastasisentrez?db¼gene) are b-galactosidase (957271), Col1a1 (12842), Col3a1
(1281), Col6a2 (12834), Fbln2 (14115), Fbn1 (14118), Mfap5 (50530), Ppib
(19035), Rrp1b (72462), RRP1B (23076), Sipa1(20469), Serpinf1 (20317),
and Serping1(12258).
Accession numbers for probe sets mentioned in this paper from the
Affymetrix NetAffx Analysis Center (http://www.affymetrix.com/
analysis/index.affx) are Col3a1 (1427884_at), Col1a1
(1423669_at_A, 1455494_at_A), Col1a2 (1423110_at_A,
1446326_at_B, 1450857_a_at_A), Fbn1(1425896_a_at), Fbln2
(1423407_a_at), Mfap5-pending (1418454_at), Mmp2
(1439364_a_at), Mmp16 (1437568_at), Nid1 (1416808_at), Serpin-
f1(1416168_at), Serping1 (1416625_at), Timp2(1420924_at), and
Tnxb (1450798_at).
Accession number for the polymorphism mentioned in this paper
from the Entrez SNP database (http://www.ncbi.nlm.nih.gov/sites/
entrez?db¼Snp) is Rrp1b (dbSNP ID: rs9306160; 1421G!A, Pro436Leu)
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